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A B S T R A C T
Heart rate reduction plays a pivotal role in the management of myocardial ischemia 
and chronic stable angina. Rate-slowing drugs, such as beta-blockers are considered 
the cornerstone of antianginal therapy. However, the broad use of beta-blockers is 
limited by their side-effects. Ivabradine is the representative of a new class of agents 
that exclusively reduce heart rate through inhibition of the sinoatrial pacemaker (If) 
current. Ivabradine reduces cardiac heart rate in doses that do not affect other ionic 
currents, resulting in a decrease in cardiac oxygen consumption and in an increase in 
diastolic period. Ivabradine has no negative inotropic or lusitropic effects, and does 
not change any major electrophysiological parameter. Large randomized trials have 
provided evidence for its efficacy in stable angina and have demonstrated anti-isch-
emic properties similar to atenolol and amlodipine. Moreover, ivabradine provides 
an attractive alternative to conventional therapy, whenever use of beta-blockers or 
calcium-channel blockers is contraindicated. Treatment of sinus tachyarrhythmias is 
another area where the use of ivabradine seems promising. Ongoing trials with ivabra-
dine will determine its effect on mortality and morbidity in patients with coronary 
artery disease and left ventricular dysfunction. 
H E A R T  R A T E  R E D U C T I O N  I N  T H E  T H E R A P Y  O F  A N G I N A
Heart rate has been identified as an independent prognostic risk factor for 
mortality from cardiovascular diseases. Large-scale epidemiological studies, such 
as the Framingham Heart Study, showed that high resting heart rate correlates 
with increased all-cause and cardiovascular mortality [1]. Several mechanisms can 
explain this phenomenon. Accelerated heart rate is involved in the progression of 
atherosclerosis through mechanical and metabolic processes. Increased wall stress, 
resulting from tachycardia, may induce endothelial injury and easier penetration of 
lipids into the vessel wall, a mechanism which could also explain the higher incidence 
of atherosclerotic plaque disruption and new acute coronary events in patients with 
high resting heart rate [2,3]. Elevated heart rate usually reflects activation of the 
sympathetic nervous system with its attendant deleterious metabolic effects resulting 
in accelerated atherogenesis.
Heart rate reduction plays a pivotal role in the management of myocardial ischemia 
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and chronic stable angina. It is well documented that myocar-
dial ischemia can result from a mismatch between myocardial 
oxygen demand and supply. Heart rate is a major determinant 
of oxygen consumption and metabolic demand. Moreover, 
higher heart rate may induce or exacerbate ischemia and 
symptoms of angina, because it shortens the duration of dia-
stole and subsequently decreases the perfusion of epicardial 
coronary arteries. This observation explains why rate-slowing 
drugs, such as beta-blockers, followed by calcium channel an-
tagonists, are considered to be the cornerstone of antianginal 
therapy. The broad use of beta-blockers is limited by their side 
effects: fatigue, lethargy, insomnia, negative inotropic and lu-
sitropic effect, depression and erectile dysfunction in men. In 
addition, beta-blockers are contraindicated in decompensated 
heart failure, chronic obstructive lung disease, peripheral vas-
cular disease, severe atrioventricular conduction defects and 
finally, Prinzmetal angina related to coronary artery spasm. In 
this latter category of patients, with angiographically normal 
coronary arteries, beta-blockers might even exacerbate symp-
toms of angina due to unopposed a-receptor activation. 
Angina is very common, despite the use of a combina-
tion of anti-anginal agents, restricting the quality of life of 
patients suffering from it. Revascularization has certainly 
improved outcomes, but symptoms of angina continue to 
be experienced by up to 60% of patients, as shown in the 
RITA2 trial [4]. New agents are needed to improve therapy 
of angina. Ivabradine is the representative of a novel class of 
agents that exclusively reduce heart rate through inhibition 
of the sinoatrial If current. 
T H E  R O L E  O F  C A R D I A C  P A C E M A K E R  
( I F )  C U R R E N T
The sinoatrial node is the normal pacemaker of the heart, 
because action potentials begin earlier in this area than other 
regions, including the atrioventricular node, the bundle of His 
and the Purkinje fibers. The pacemaker cells are hyperpolar-
ized at rest. At the next point, a slow diastolic depolarization 
begins, which turns the membrane voltage to the threshold 
level for a new action potential. The rate of depolarization 
actually reflects the heart rate [5]. The If current determines 
the slope of the depolarization curve towards the threshold 
level, which is –40 mV in humans. In this manner, time inter-
val between action potentials, which in turn is expressed in 
the heart rhythm, is regulated by this inward Na+/K+ current 
known as the If current of the sinoatrial node.
The pacemaker current in the sinoatrial node, a slowly 
activated inward current, termed “funny” (If current) due to 
its atypical properties, was discovered in 1979 by Brown et al 
[6]. There are three other ionic currents in the sinoatrial node 
cells that are all together responsible for spontaneous diastolic 
depolarization: the outward potassium current (Ik), the long-
lasting calcium (Ical) and the transient calcium current (Icat). 
The If current is slowly activated during the hyperpolarization 
state. In the heart, If generates spontaneous activity and me-
diates autonomic neurotransmitter control of the heart rate. 
The “funny” (f) channels are hyperpolarization-activated, 
cyclonucleotide-gated (HCN) ion channels, whose cloning 
was accomplished in the late 1990s. HCN channels are found 
in the heart, retina and brain. The HCN1, HCN2 and HCN4 
isoforms are expressed in the heart. The HCN4 isoform is 
mostly found in the sinoatrial node. These channels are active 
only in the sinoatrial node under normal circumstances, hence 
their relevance to regular pacemaker activity, but they might be 
active in other regions of the heart, such as the atrioventricular 
node and the Purkinje fibres, in pathological conditions like 
heart failure and hypertrophic cardiomyopathy [7]. There are 
indications that mutations of HCN4 may be linked to sinus 
node dysfunction [8].
The finding that If controls the heart rate has had a great 
impact on our understanding of the physiologic mechanisms 
underlying cardiac function, but it has also directed us to pos-
sible ways to influence heart rate and hence cardiac function 
by pharmacological agents or other means. Indeed, agents 
that selectively block the f channels, such as ivabradine, act 
as “pure” heart rate-reducing drugs and offer a potential for 
therapeutic intervention in diseases where heart rate reduction 
is of benefit, such as angina and heart failure. On a different 
note, molecular biology and recombinant DNA techniques 
may allow us to produce biological pacemakers by restoring 
pacing function in defective pacing cells or transforming 
regular cardiac cells into pacing cells, by transfection of HCN 
channels, thus replacing electronic devices in the future! 
I V A B R A D I N E ,  A  S P E S I F I C  
A N D  S E L E C T I V E  I F  I N H I B I T O R
The molecule of ivabradine binds specifically to the HCN4 
channel on the intracellular side of the sinoatrial cell mem-
brane and inhibits the f current upon depolarization, which 
is when the channel is open. Ivabradine is then released by 
the channel during the closing phase of hyperpolarization [9]. 
Inhibition of the f current results in a decrease in the slope 
of diastolic depolarization curve, which in turn increases the 
time interval between effective action potentials leading to a 
reduction of heart rate [10]. The inhibition of the f channel 
is current-dependent, meaning that the higher the heart rate 
the more effective is ivabradine. Ivabradine is a selective If 
current inhibitor in concentrations used for clinical practice, 
whereas other currents become affected in higher doses. It 
has no effect on T-type Ca2+ channels, whereas the L-type 
Ca2+ channels are slightly inhibited in doses 60 times greater 
than the therapeutic dose in animal experiments [11]. This is 
why ivabradine affects heart rate without reducing myocardial 
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contractility. No significant effect on Na+ or K+ currents has 
been demonstrated with these experimental models. 
Other selective If inhibitors have been proposed for use 
in practice. Alinidine is a selective agent that induces brady-
cardia, but showed a negative inotropic action in an animal 
experimental model [12]. Zatebradine is a compound with 
both selective and specific f channel inhibition properties 
that entered late-phase clinical testing. Although heart rate 
reduction was achieved both at rest and during exercise, the 
drug was abandoned because of severe ocular side-effects. 
The explanation for this is probably the fact that zatebradine 
exhibits its therapeutic effects in doses which substantially 
inhibit the HCN channels in the retina [13,14]. Ivabradine, first 
reported more than a decade ago, exhibits a unique specific-
ity for the If current with a more favorable profile of adverse 
reactions than zatebradine [15]. Ivabradine has been used in 
the treatment of stable angina, an area where it displays anti-
anginal and antischemic effects equivalent to the effects of 
atenolol and amlodipine.
C L I N I C A L  T R I A L S  O F  I V A B R A D I N E  I N  
S T A B L E  A N G I N A
The first large randomized double-blinded trial of ivabra-
dine as monotherapy involved 360 patients (Table 1) [16]. The 
aim of the trial was to prove whether ivabradine has anti-an-
ginal properties, whether the effects persist during 3 months 
of continual use and finally if there is a rebound phenomenon 
of ischemia after abrupt cessation of the drug. Patients were 
randomized to placebo or to one of the doses of ivabradine 
(2.5, 5, or 10 mg twice daily) [16]. The variables used to as-
sess drug efficacy were exercise tolerance during treadmill 
testing, ST segment variation and angina frequency in daily 
life. The drug reduced heart rate at rest and during exercise, 
with little change in blood pressure compared to placebo. 
Exercise-induced angina was less in the ivabradine arm and 
dose-dependent, as measured by time to 1mm ST segment 
depression. Angina attack rate requiring use of nitroglycerin 
was lower on ivabradine compared to placebo. Cessation of 
ivabradine does not lead to rebound effects, unlike short-
acting beta-blockers, while no pharmacological tolerance is 
exhibited after prolonged use, a problem commonly seen with 
long-acting nitrates.
In the International Trial of the Antianginal effects of 
Ivabradine compared to atenolol (INITIATIVE), 939 patients 
with stable angina were randomized to receive ivabradine or 
atenolol [17]. Ivabradine, in doses of 7.5 and 10 mg bid, was 
not inferior to atenolol 100 mg once daily, in terms of their 
anti-anginal and anti-ischemic effects as demonstrated with 
an increase in total exercise duration and increase in time to 
1 mm ST segment depression [17].
A large clinical trial compared ivabradine with the cal-
cium –channel blocker amlodipine [18]. In this trial 1195 
patients with stable angina were randomized to receive 7.5 to 
10 mg ivabradine bid or 10 mg amlodipine once daily. Again 
ivabradine was proven to be as efficacious as amlodipine in 
preventing angina attacks [18].
The efficacy and safety of combination therapy with ivabra-
dine has been demonstrated in a randomized, double-blind, 
multi-center trial conducted in 386 patients with stable angina 
already treated with nitrates or dihydropyridine calcium-chan-
nel blockers, who received ivabradine for 1 year in doses of 
5 and 7.5 mg bid [19]. Ivabradine decreased heart rate in a 
dose-dependent manner and the reduction was constant over 
one year of follow-up. The number of angina attacks reported 
by patients was significantly lower after the addition of ivabra-
dine to therapy [19].
A small double-blind study, comparing the effects of 
ivabradine and propranolol on systemic and cardiac hemo-
dynamics at rest and during exercise, was conducted with 
nine healthy volunteers receiving ivabradine, or propranolol, 
or placebo [20]. This study demonstrated that, for a similar 
heart rate reduction at rest and during sympathetic activation, 
administration of ivabradine reduced myocardial oxygen de-
mand at the same degree as propranolol, but without negative 
inotropic effect [20].
Ivabradine is generally well tolerated. The only side-
effects mentioned in clinical trials were visual, including 
phosphenes, stroboscopic effect and non-typical blurred 
vision. Visual symptoms were dose-related, reversible with 
drug cessation and generally not bothersome enough to cause 
voluntary withdrawal of the drug. During the clinical devel-
opment program of ivabradine for angina prevention, visual 
side-effects were reported in 2-15% of 5000 patients involved 
TABLE 1. Randomized Trials of Ivabradine in Stable 
Angina
Study Patients Follow-up  Results
 Borer et al [16] 360 3 months dose-dependent
    improvement in
    exercise tolerance
 INITIATIVE [17] 939 4 months decrease in anginal
    attacks by 2/3 with
    both ivabradine &
    atenolol (non-
    inferiority of
    ivabradine)
 Ruzyllo et al [18] 1195 3 months ivabradine as
    effective and safe as
    amlodipine
 Lopez-Bescos 386 12 months ivabradine was safe
 et al [19]    and well-tolerated at
    doses of 5 and 7.5 mg
    bid
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and led to drug discontinuation in less than 1% [21]. Patients 
with sick sinus syndrome and atrial fibrillation cannot receive 
ivabradine, because the sinoatrial node is the sole target of 
the drug. Ivabradine does not affect the conduction system 
of the heart and does not alter electrocardiographic PR and 
corrected QT intervals.
In summary, ivabradine is the first selective If current in-
hibitor that has completed clinical development and assess-
ment for stable angina. It reduces cardiac heart rate in doses 
that do not affect other ionic currents, resulting in a decrease 
in cardiac oxygen consumption and in an increase in diastolic 
period. Ivabradine has no negative inotropic or lusitropic ef-
fects, and does not change any major electrophysiological pa-
rameter. Its efficacy in stable angina has been shown in large 
randomized trials which have demonstrated its anti-ischemic 
properties, found to be similar to atenolol and amlodipine. 
Moreover, ivabradine provides an attractive alternative to 
conventional therapy, whenever use of beta-blockers or cal-
cium-channel blockers is contraindicated. Treatment of sinus 
tachyarrhythmias is another era where the use of ivabradine 
seems promising [22]. Current trials, such as the BEAUTI-
FUL study, will answer to questions about the effect of this 
regimen on mortality and morbidity in patients with coronary 
artery disease and left ventricular dysfunction.
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